A systematic review of bisphosphonate osteonecrosis (BON) in cancer

Cesar Augusto Migliorati; Sook-Bin Woo; Ian Hewson; Andrei Barasch; Linda S. Elting; Fred K. L. Spijkervet; Michael T. Brennan; MASCC ISOO

doi:10.1007/s00520-010-0882-1

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

Cesar Augusto Migliorati^*, Sook-Bin Woo, Ian Hewson, Andrei Barasch, Linda S. Elting, Fred K. L. Spijkervet, Michael T. Brennan, MASCC ISOO

^*Corresponding author for this work

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Review article › peer-review

85 Citations (Scopus)

Abstract

This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues.

A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON.

A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%.

High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.

Original language	English
Pages (from-to)	1099-1106
Number of pages	8
Journal	Supportive Care in Cancer
Volume	18
Issue number	8
DOIs	https://doi.org/10.1007/s00520-010-0882-1
Publication status	Published - Aug-2010

Keywords

Cancer therapy
Bisphosphonate osteonecrosis
Bisphosphonate therapy
Management strategies
MULTIPLE-MYELOMA PATIENTS
RISK-FACTORS
PROSTATE-CANCER
JAW ONJ
MICROBIAL BIOFILMS
ZOLEDRONIC ACID
POSITION PAPER
THERAPY
MANAGEMENT
FREQUENCY

Access to Document

10.1007/s00520-010-0882-1

Handle.net

Persistent link

Cite this

@article{3b9fe383227d4592839ebceb710ede30,

title = "A systematic review of bisphosphonate osteonecrosis (BON) in cancer",

abstract = "This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues.A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON.A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%.High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.",

keywords = "Cancer therapy, Bisphosphonate osteonecrosis, Bisphosphonate therapy, Management strategies, MULTIPLE-MYELOMA PATIENTS, RISK-FACTORS, PROSTATE-CANCER, JAW ONJ, MICROBIAL BIOFILMS, ZOLEDRONIC ACID, POSITION PAPER, THERAPY, MANAGEMENT, FREQUENCY",

author = "Migliorati, {Cesar Augusto} and Sook-Bin Woo and Ian Hewson and Andrei Barasch and Elting, {Linda S.} and Spijkervet, {Fred K. L.} and Brennan, {Michael T.} and {MASCC ISOO}",

year = "2010",

month = aug,

doi = "10.1007/s00520-010-0882-1",

language = "English",

volume = "18",

pages = "1099--1106",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - A systematic review of bisphosphonate osteonecrosis (BON) in cancer

AU - Migliorati, Cesar Augusto

AU - Woo, Sook-Bin

AU - Hewson, Ian

AU - Barasch, Andrei

AU - Elting, Linda S.

AU - Spijkervet, Fred K. L.

AU - Brennan, Michael T.

AU - MASCC ISOO

PY - 2010/8

Y1 - 2010/8

N2 - This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues.A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON.A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%.High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.

AB - This systematic review aims to examine the prevalence of bisphosphonate osteonecrosis (BON) in the cancer population, prevention and treatment protocols, and quality of life issues.A search of MEDLINE/PubMed and EMBASE form October 2003 to December 31, 2008 was conducted with the objective of identifying publications that contained original data regarding BON.A total of 28 publications fulfilled inclusion criteria, but only 22 were used for prevalence analysis. No randomized controlled clinical trials, meta-analysis, or quality of life papers were found that contained information regarding either prevalence or treatment protocols for the management of BON. The overall weighted prevalence of BON included a sample of 39,124 patients with a mean weighted prevalence of 6.1%. The weighted prevalence was 13.3% for studies with documented follow-up with a sample size of 927 individuals. The weighted prevalence in studies with undocumented follow-up was 0.7% in a sample of 8,829 chart reviews. Epidemiological studies evaluated a total of 29,368 individual records, and the weighted BON prevalence was 1.2%.High-quality studies are needed to accurately characterize the prevalence of BON, and to determine effective treatment protocols.

KW - Cancer therapy

KW - Bisphosphonate osteonecrosis

KW - Bisphosphonate therapy

KW - Management strategies

KW - MULTIPLE-MYELOMA PATIENTS

KW - RISK-FACTORS

KW - PROSTATE-CANCER

KW - JAW ONJ

KW - MICROBIAL BIOFILMS

KW - ZOLEDRONIC ACID

KW - POSITION PAPER

KW - THERAPY

KW - MANAGEMENT

KW - FREQUENCY

U2 - 10.1007/s00520-010-0882-1

DO - 10.1007/s00520-010-0882-1

M3 - Review article

SN - 0941-4355

VL - 18

SP - 1099

EP - 1106

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 8

ER -

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this